Next Article in Journal
The Spatial-Temporal Variation Characteristics of Natural Vegetation Drought in the Yangtze River Source Region, China
Next Article in Special Issue
Association of CX3CR1 Gene Polymorphisms with Fractalkine, Fractalkine Receptor, and C-Reactive Protein Levels in Patients with Kidney Failure
Previous Article in Journal
Residential Greenspace and Urban Adolescent Substance Use: Exploring Interactive Effects with Peer Network Health, Sex, and Executive Function
Previous Article in Special Issue
Hyperhomocysteinemia Concurrent with Metabolic Syndrome Is Independently Associated with Chronic Kidney Disease among Community-Dwelling Adults in an Urban Korean Population
Review

Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?

Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Poniatowskiegostr., 40-055 Katowice, Poland
*
Author to whom correspondence should be addressed.
Academic Editor: Paul B. Tchounwou
Int. J. Environ. Res. Public Health 2021, 18(4), 1612; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18041612
Received: 30 December 2020 / Revised: 29 January 2021 / Accepted: 30 January 2021 / Published: 8 February 2021
(This article belongs to the Special Issue Obesity, Diabetes and Chronic Kidney Disease)
In patients with chronic kidney disease (CKD), anemia develops gradually, which is primarily due to an inadequate synthesis of erythropoietin by the kidneys, as well as to iron disorders in the body, blood loss, shortened erythrocyte survival and inflammation. The currently accepted treatment employs iron, vitamin B12, folic acid supplementation and the use of erythropoiesis stimulants, which are administered only parenterally. Research is currently underway on the new erythropoiesis drugs that can be orally administered, i.e., hypoxia-inducible factor-propyl hydroxylase inhibitor (HIF-PHI) inhibitors which temporarily block propyl hydroxylase [PHD] catalysis and promote a transient increase in the expression of genes regulated by HIF, including kidney and liver erythropoietin [EPO]. Roxadustat is the first oral drug in this class and a potent HIF-PHD inhibitor, exerted to treat anemia in patients with CKD. In phase 1, 2 and 3 studies with CKD-affected patients, roxadustat was more effective to stimulate erythropoiesis for anemia correction than previously used drugs. Roxadustat can be orally given, unlike other erythropoiesis drugs with parenteral administration only, which grants roxadustat a considerable advantage. Our paper presents the results of studies with roxadustat applied for the treatment of anemia in CKD patients with or without dialysis. We are currently not yet able to know the exact role of roxadustat in the treatment of anemia in patients with CKD, but time will tell. It is possible that roxadustat has benefits an iron metabolism and cardiovascular risk. View Full-Text
Keywords: chronic kidney disease; anemia; roxadustat chronic kidney disease; anemia; roxadustat
Show Figures

Figure 1

MDPI and ACS Style

Grzeszczak, W.; Szczyra, D.; Śnit, M. Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future? Int. J. Environ. Res. Public Health 2021, 18, 1612. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18041612

AMA Style

Grzeszczak W, Szczyra D, Śnit M. Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future? International Journal of Environmental Research and Public Health. 2021; 18(4):1612. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18041612

Chicago/Turabian Style

Grzeszczak, Władysław, Dariusz Szczyra, and Mirosław Śnit. 2021. "Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?" International Journal of Environmental Research and Public Health 18, no. 4: 1612. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18041612

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop